SEPRACOR INC /DE/
10-Q, EX-27.1, 2000-11-08
PHARMACEUTICAL PREPARATIONS
Previous: SEPRACOR INC /DE/, 10-Q, 2000-11-08
Next: SALTON INC, 8-K, 2000-11-08



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                     266,248,000
<SECURITIES>                               413,273,000
<RECEIVABLES>                                8,059,000
<ALLOWANCES>                                   279,000
<INVENTORY>                                  6,477,000
<CURRENT-ASSETS>                           666,134,000
<PP&E>                                      35,917,000
<DEPRECIATION>                              15,635,000
<TOTAL-ASSETS>                             798,003,000
<CURRENT-LIABILITIES>                       72,388,000
<BONDS>                                    852,843,000
                                0
                                          0
<COMMON>                                     7,365,000
<OTHER-SE>                               (144,063,000)
<TOTAL-LIABILITY-AND-EQUITY>               798,003,000
<SALES>                                     33,680,000
<TOTAL-REVENUES>                            60,868,000
<CGS>                                        7,786,000
<TOTAL-COSTS>                               10,635,000
<OTHER-EXPENSES>                           175,123,000
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                          35,286,000
<INCOME-PRETAX>                          (130,571,000)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                      (130,571,000)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                             (130,571,000)
<EPS-BASIC>                                     (1.80)
<EPS-DILUTED>                                   (1.80)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission